📈 GHRH + GHS Blend

Tesamorelin + Ipamorelin Blend (10 mg) Dosage Protocol

Tesamorelin is a GHRH analog with the strongest clinical evidence base of any GHRH peptide — FDA approved for HIV-associated lipodystrophy. Combined with ipamorelin, this blend pairs tesamorelin's GHRH-receptor-mediated GH pulse amplification with ipamorelin's selective ghrelin-receptor GH secretion for synergistic effect.

⚡ Quickstart Highlights

Reconstitution

3.0 mL BAC water → 3.33 mg/mL total (1.67 mg/mL each)

Per-Dose Range

100–300 mcg of each

1 U-100 Unit =

33.3 mcg total

Tesamorelin HL

~26 minutes

Dosing & Reconstitution Guide

Route: Subcutaneous | Frequency: Once or twice daily, empty stomach

Phase	Dose Per Injection	Frequency	U-100 Units	Notes
Weeks 1–4	100 mcg each	Once daily	6 units	Conservative start
Weeks 5–12	200 mcg each	Once or twice daily	12 units	Standard range
Extended	300 mcg each	Once daily	18 units	Tesamorelin matches FDA-approved 2 mg/day dose at this level

The FDA-approved tesamorelin dose for HIV lipodystrophy is 2 mg/day subcutaneous. This blend at 200 mcg tesamorelin approaches lower research doses; higher doses can be achieved by increasing volume. Tesamorelin has the strongest visceral fat evidence of any GHRH analog based on Phase 3 trial data.

Reconstitution Steps

Draw 3.0 mL bacteriostatic water into a sterile syringe.
Inject slowly down the inside glass wall of the vial; avoid foaming.
Gently swirl until dissolved. Do not shake.
Label with reconstitution date. Refrigerate at 2–8°C; use within 28 days.

Supplies Planning

Item	12 Weeks (200 mcg 1×/day)	12 Weeks (200 mcg 2×/day)
Tesamorelin+Ipa vials (10 mg)	4–5 vials	8–9 vials
Insulin syringes (30–50 unit)	84	168
BAC water (10 mL)	2 × 10 mL	3 × 10 mL
Alcohol swabs	2 × 100-pack	3 × 100-pack

Mechanism of Action

Tesamorelin is a synthetic analog of GHRH conjugated to a trans-3-hexenoic acid group that confers stability against serum dipeptidyl peptidase IV (DPP-IV) degradation. Its half-life of ~26 minutes is longer than natural GHRH (~7 minutes) while remaining short enough to produce pulsatile rather than continuous GH release.

FDA Phase 3 trials in HIV lipodystrophy demonstrated significant visceral adipose tissue reduction — making tesamorelin the only GHRH analog with Phase 3 RCT evidence for body composition improvement in humans. When combined with ipamorelin, complementary receptor pathways (GHRH + ghrelin receptors) produce synergistic GH pulse amplification. Ipamorelin's selectivity (no cortisol/ACTH elevation) makes it the ideal GHRP partner for tesamorelin.

Research Findings & Safety Profile

Only GHRH analog with FDA approval (Egrifta — for HIV-associated lipodystrophy) and Phase 3 clinical evidence for body composition.
Phase 3 trials: significant visceral adipose tissue reduction, improved trunk fat/lean mass ratio.
Paired with ipamorelin for complementary GH secretion pathways without cortisol elevation.
Tesamorelin's DPP-IV stability extends half-life beyond natural GHRH while preserving pulsatile release kinetics.
Well-characterized safety profile from Phase 3 program; injection-site reactions most common adverse effect.
WADA prohibited. Tesamorelin (Egrifta) is FDA-approved by prescription for specific indication only.

Storage

State	Temperature	Duration	Notes
Lyophilized	−20°C (−4°F)	Up to 24 months	Dry, dark conditions
Reconstituted	2–8°C (35–46°F)	Up to 28 days	Avoid freeze-thaw; protect from light

⚠ Research Use Only: Tesamorelin is FDA-approved (Egrifta) for HIV lipodystrophy only; research-grade use in other contexts is investigational. WADA prohibited. Best GHRH analog evidence base of any compound on this site.

References

Falutz J et al. 'Metabolic effects of a growth hormone-releasing factor in patients with HIV' — NEJM, 2007 View source ↗

Stanley TL et al. 'Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation' — JAMA, 2012 View source ↗